EP0998585A4 - Screening methods using an atpase protein from a virus of the flaviviridae family - Google Patents
Screening methods using an atpase protein from a virus of the flaviviridae familyInfo
- Publication number
- EP0998585A4 EP0998585A4 EP98931775A EP98931775A EP0998585A4 EP 0998585 A4 EP0998585 A4 EP 0998585A4 EP 98931775 A EP98931775 A EP 98931775A EP 98931775 A EP98931775 A EP 98931775A EP 0998585 A4 EP0998585 A4 EP 0998585A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- virus
- screening methods
- flaviviridae family
- atpase protein
- atpase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5158297P | 1997-07-02 | 1997-07-02 | |
US51582P | 1997-07-02 | ||
PCT/US1998/013790 WO1999001582A1 (en) | 1997-07-02 | 1998-07-01 | Screening methods using an atpase protein from a virus of the flaviviridae family |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0998585A1 EP0998585A1 (en) | 2000-05-10 |
EP0998585A4 true EP0998585A4 (en) | 2004-11-10 |
EP0998585B1 EP0998585B1 (en) | 2007-08-29 |
Family
ID=21972179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98931775A Expired - Lifetime EP0998585B1 (en) | 1997-07-02 | 1998-07-01 | Screening methods using an atpase protein from a virus of the flaviviridae family |
Country Status (8)
Country | Link |
---|---|
US (1) | US6010848A (en) |
EP (1) | EP0998585B1 (en) |
JP (1) | JP2002511763A (en) |
AU (1) | AU8180598A (en) |
CA (1) | CA2289453A1 (en) |
DE (1) | DE69838328T2 (en) |
WO (1) | WO1999001582A1 (en) |
ZA (1) | ZA985762B (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE292511T1 (en) * | 1998-11-23 | 2005-04-15 | Zenon Environmental Inc | WATER FILTRATION USING UNDERWATER MEMBRANES |
US7166475B2 (en) * | 1999-02-26 | 2007-01-23 | Cyclacel Ltd. | Compositions and methods for monitoring the modification state of a pair of polypeptides |
US6540996B1 (en) * | 1999-04-15 | 2003-04-01 | Devgen Nv | Compound screening methods |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
AU2002330154A1 (en) * | 2001-09-28 | 2003-04-07 | Centre National De La Recherche Scientifique | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
ES2386161T3 (en) | 2003-04-16 | 2012-08-10 | Bristol-Myers Squibb Company | Process to separate a mixture of alkyl ester enantiomers using an enzyme |
US7582428B2 (en) | 2003-08-22 | 2009-09-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying anti-HCV agents |
TWI294036B (en) * | 2005-02-24 | 2008-03-01 | Tzu Chi Buddhist General Hospital | A method for screening compounds against flaviviruses infection by using persistent virus-infected cell systems |
CA2612340A1 (en) * | 2005-06-15 | 2006-12-28 | The Trustees Of The University Of Pennsylvania | Detection of hiv-1 infection |
WO2008073165A2 (en) | 2006-08-25 | 2008-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying anti-hcv agents |
WO2008134640A2 (en) * | 2007-04-26 | 2008-11-06 | Achillion Pharmaceuticals, Inc. | Cells expressing chimeric ns4a proteins of hcv and their use in assays |
WO2009005615A1 (en) | 2007-06-27 | 2009-01-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying agents that inhibit an ns4b-mediated neoplastic cellular phenotype of hcv infected cells |
AU2009322393B2 (en) | 2008-12-03 | 2017-02-02 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
EP2373168A4 (en) | 2008-12-03 | 2012-08-01 | Presidio Pharmaceuticals Inc | Inhibitors of hcv ns5a |
MX2011010132A (en) | 2009-03-27 | 2011-10-14 | Presidio Pharmaceuticals Inc | Fused ring inhibitors of hepatitis c. |
US8877707B2 (en) | 2010-05-24 | 2014-11-04 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
WO2012020036A1 (en) | 2010-08-13 | 2012-02-16 | F. Hoffmann-La Roche Ag | Hepatitis c virus inhibitors |
WO2012123298A1 (en) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Antiviral compounds |
WO2012175581A1 (en) | 2011-06-24 | 2012-12-27 | F. Hoffmann-La Roche Ag | Antiviral compounds |
JP5808496B2 (en) | 2011-10-10 | 2015-11-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Antiviral compounds |
JP5923181B2 (en) | 2011-12-16 | 2016-05-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Inhibitor of HCVNS5A |
ES2626484T3 (en) | 2011-12-20 | 2017-07-25 | Riboscience Llc | 4'-azido-3'-fluoro-substituted nucleoside derivatives as inhibitors of HCV RNA replication |
WO2013092481A1 (en) | 2011-12-20 | 2013-06-27 | F. Hoffmann-La Roche Ag | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication |
JP6092261B2 (en) | 2012-02-24 | 2017-03-08 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Antiviral compounds |
US20140010783A1 (en) | 2012-07-06 | 2014-01-09 | Hoffmann-La Roche Inc. | Antiviral compounds |
JP6096324B2 (en) | 2013-01-23 | 2017-03-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Antiviral triazole derivatives |
US9428469B2 (en) | 2013-03-05 | 2016-08-30 | Hoffmann-La Roche | Antiviral compounds |
US20180200280A1 (en) | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
MA38678A1 (en) | 2013-05-16 | 2017-07-31 | Riboscience Llc | Nucleoside derivatives 4'-azido, 3'-deoxy-3'-fluoro substituted |
CA2912682C (en) | 2013-05-16 | 2021-07-06 | Riboscience Llc | 4'-fluoro-2'-methyl substituted nucleoside derivatives |
JP7299897B2 (en) | 2017-09-21 | 2023-06-28 | リボサイエンス リミティド ライアビリティ カンパニー | 4'-Fluoro-2'-methyl-substituted Nucleoside Derivatives as HCV RNA Replication Inhibitors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0318216A1 (en) * | 1987-11-18 | 1989-05-31 | Chiron Corporation | NANBV diagnostics and vaccines |
WO1995029897A1 (en) * | 1994-04-29 | 1995-11-09 | G.D. Searle & Co. | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS |
WO1996036702A2 (en) * | 1995-05-12 | 1996-11-21 | Schering Corporation | Soluble, active hepatitis c virus protease |
-
1998
- 1998-06-19 US US09/100,557 patent/US6010848A/en not_active Expired - Fee Related
- 1998-07-01 WO PCT/US1998/013790 patent/WO1999001582A1/en active IP Right Grant
- 1998-07-01 CA CA002289453A patent/CA2289453A1/en not_active Abandoned
- 1998-07-01 JP JP50737699A patent/JP2002511763A/en active Pending
- 1998-07-01 ZA ZA985762A patent/ZA985762B/en unknown
- 1998-07-01 AU AU81805/98A patent/AU8180598A/en not_active Abandoned
- 1998-07-01 EP EP98931775A patent/EP0998585B1/en not_active Expired - Lifetime
- 1998-07-01 DE DE69838328T patent/DE69838328T2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0318216A1 (en) * | 1987-11-18 | 1989-05-31 | Chiron Corporation | NANBV diagnostics and vaccines |
WO1995029897A1 (en) * | 1994-04-29 | 1995-11-09 | G.D. Searle & Co. | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS |
WO1996036702A2 (en) * | 1995-05-12 | 1996-11-21 | Schering Corporation | Soluble, active hepatitis c virus protease |
Non-Patent Citations (2)
Title |
---|
KIM D W ET AL: "C-TERMINAL DOMAIN OF THE HEPATITIS C VIRUS NS3 PROTEIN CONTAINS AN RNA HELICASE ACTIVITY", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 215, no. 1, 4 October 1995 (1995-10-04), pages 160 - 166, XP002035618, ISSN: 0006-291X * |
See also references of WO9901582A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2002511763A (en) | 2002-04-16 |
ZA985762B (en) | 1999-01-19 |
EP0998585B1 (en) | 2007-08-29 |
DE69838328T2 (en) | 2008-05-21 |
CA2289453A1 (en) | 1999-01-14 |
US6010848A (en) | 2000-01-04 |
DE69838328D1 (en) | 2007-10-11 |
EP0998585A1 (en) | 2000-05-10 |
AU8180598A (en) | 1999-01-25 |
WO1999001582A1 (en) | 1999-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA985762B (en) | Screening methods using an atpase protein from a virus of the flaviviridae family | |
PL335721A1 (en) | Novel methods of screening serving the purpose of identifying the factors of selective hepatitis c virus replication inhibition | |
IL171896A0 (en) | Fusion protein comprising a hcv ns3 helicase fragment | |
ID24201A (en) | RECOVERY OF EGG WASTE COMPONENTS | |
FR2770899B1 (en) | VIBRATING MICROGYROMETER | |
ZA9811316B (en) | Novel hepatitis C virus NS5B protein | |
IL137952A0 (en) | Method for designing dna-binding proteins of the zinc-finger class | |
DE69834986D1 (en) | Toner and imaging process | |
DE69833039D1 (en) | SEPARATION PROCESS | |
NO20011843L (en) | Selectively replicating virus vectors | |
EP1038037A4 (en) | Screening assays for the detection and diagnosis of influenza virus | |
IL146743A0 (en) | Screening method for peptides | |
DE19581726T1 (en) | Horizontal vibrating centrifuge | |
IT1288107B1 (en) | SCREENING SHELL | |
EP1113777A4 (en) | Novel hepatitis c virus peptides and uses thereof | |
GB9701245D0 (en) | Method of screening compounds | |
GB2324224B (en) | Method of call screening | |
ATA186997A (en) | SCREENING | |
GB0126386D0 (en) | Screening methods based on cited family proteins | |
DE69916516D1 (en) | vibrating Screen | |
GB9713667D0 (en) | Enhancement of intestinal permeability | |
EP1129178A4 (en) | A sensitive screening system for envelope-defective recombinant virus | |
ATA84697A (en) | SCREENING | |
KR960000397U (en) | Mesh of vibrating sorter | |
GB9706078D0 (en) | Screening method and proteins and dna identified thereby |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE DK FR GB IT LI NL |
|
17P | Request for examination filed |
Effective date: 20000202 |
|
RTI1 | Title (correction) |
Free format text: SCREENING METHODS USING AN ATPASE PROTEIN FROM A VIRUS OF THE FLAVIVIRIDAE FAMILY |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SMITHKLINE BEECHAM CORPORATION |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SMITHKLINE BEECHAM CORPORATION |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040924 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7G 01N 33/576 B Ipc: 7A 61K 39/29 B Ipc: 7A 61K 38/43 B Ipc: 7G 01N 33/53 B Ipc: 7C 12Q 1/42 B Ipc: 7C 12Q 1/70 A |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE DK FR GB IT LI NL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69838328 Country of ref document: DE Date of ref document: 20071011 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070829 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
ET | Fr: translation filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070829 Ref country code: LI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070829 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070829 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20080530 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20080731 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20080718 Year of fee payment: 11 Ref country code: FR Payment date: 20080707 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20080616 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1028792 Country of ref document: HK |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20080730 Year of fee payment: 11 |
|
BERE | Be: lapsed |
Owner name: SMITHKLINE BEECHAM CORP. Effective date: 20090731 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20090701 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20100331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100202 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090701 |